To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Sonoma Biotherapeutics rakes in Series A
South San Francisco and Seattle-based Sonoma Biotherapeutics, a developer of regulatory T-cell therapies for autoimmune and degenerative diseases, has raised $30 million from investors in its Series A financing, bringing the total to $70 million.
